share_log

藥明康德:翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

HKEX ·  Sep 13 04:51

Summary by Moomoo AI

無錫藥明康德新藥開發股份有限公司(药明康德)於2024年9月11日至13日進行了股份回購活動,共回購了3,690,250股A股股份。根據香港聯合交易所有限公司(香港聯交所)證券上市規則,公司必須披露股份變動情況。回購的股份將擬註銷,並且在上海證券交易所進行。該公司於2024年9月13日的回購價格範圍為每股人民幣39.82元至40.66元,總支付價格為人民幣87,740,638.5元。公司董事李革確認,所有回購活動均已獲得董事會正式授權批准,並遵守所有適用的上市規則、法律及其他監管規定。
無錫藥明康德新藥開發股份有限公司(药明康德)於2024年9月11日至13日進行了股份回購活動,共回購了3,690,250股A股股份。根據香港聯合交易所有限公司(香港聯交所)證券上市規則,公司必須披露股份變動情況。回購的股份將擬註銷,並且在上海證券交易所進行。該公司於2024年9月13日的回購價格範圍為每股人民幣39.82元至40.66元,總支付價格為人民幣87,740,638.5元。公司董事李革確認,所有回購活動均已獲得董事會正式授權批准,並遵守所有適用的上市規則、法律及其他監管規定。
Wuxi Apptec conducted a share repurchase activity from September 11th to 13th, 2024, repurchasing a total of 3,690,250 A-shares. According to the Securities Listing Rules of the Hong Kong Stock Exchange, the company must disclose changes in shareholding. The repurchased shares will be cancelled and the transaction will take place on the Shanghai Stock Exchange. The repurchase price range on September 13th, 2024 was RMB 39.82 to 40.66 per share, with a total payment price of RMB 87,740,638.5. Director Li Ge confirmed that all repurchase activities have obtained formal approval from the Board of Directors and comply with all applicable listing rules, laws, and other regulatory requirements.
Wuxi Apptec conducted a share repurchase activity from September 11th to 13th, 2024, repurchasing a total of 3,690,250 A-shares. According to the Securities Listing Rules of the Hong Kong Stock Exchange, the company must disclose changes in shareholding. The repurchased shares will be cancelled and the transaction will take place on the Shanghai Stock Exchange. The repurchase price range on September 13th, 2024 was RMB 39.82 to 40.66 per share, with a total payment price of RMB 87,740,638.5. Director Li Ge confirmed that all repurchase activities have obtained formal approval from the Board of Directors and comply with all applicable listing rules, laws, and other regulatory requirements.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more